Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Genmab A/S has received a consensus recommendation of "Moderate Buy" from analysts, with an average price target of $40.80 for the stock.
• The company reported a $0.54 earnings per share for the last quarter, exceeding analyst expectations and having a net margin of 37.53%.
• Several investment firms have upgraded Genmab's rating recently, including a move from "buy" to "strong-buy" by Wall Street Zen.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $40.80.

A number of research firms have recently issued reports on GMAB. Wall Street Zen upgraded shares of Genmab A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, September 26th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Genmab A/S in a report on Wednesday. Truist Financial lifted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Weiss Ratings reiterated a "hold (c)" rating on shares of Genmab A/S in a report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd.

Genmab A/S Stock Performance

Shares of GMAB opened at $32.72 on Thursday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $33.63. The firm's 50 day moving average price is $27.51 and its two-hundred day moving average price is $23.13. The firm has a market cap of $21.01 billion, a P/E ratio of 16.44, a PEG ratio of 1.85 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its holdings in Genmab A/S by 28.3% during the third quarter. CWM LLC now owns 2,306 shares of the company's stock worth $71,000 after buying an additional 509 shares during the last quarter. Aaron Wealth Advisors LLC acquired a new position in Genmab A/S during the third quarter worth $228,000. GAMMA Investing LLC increased its holdings in Genmab A/S by 55.4% during the third quarter. GAMMA Investing LLC now owns 2,982 shares of the company's stock worth $91,000 after buying an additional 1,063 shares during the last quarter. Osaic Holdings Inc. increased its holdings in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock worth $33,000 after buying an additional 440 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Genmab A/S by 636.3% during the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company's stock worth $1,947,000 after buying an additional 81,434 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.